Intranasal Influenza Vaccine

2021 ◽  
Author(s):  
Gratis Research
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Seasonal Influenza ◽  
Intranasal Vaccine ◽  
Intranasal Spray

Intranasal vaccine is a novel candidate that could improve the current injectable vaccine for the to prevent seasonal influenza epidemics. Influenza intranasal spray vaccine causes a local antibody response.

Antibody response to the influenza vaccine in healthcare workers

Vaccine ◽  
2012 ◽  
Vol 30 (2) ◽  
pp. 436-441 ◽  
Author(s):  
Ema Sacadura-Leite ◽  
Antonio Sousa-Uva ◽  
Helena Rebelo-de-Andrade
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Healthcare Workers

scholarly journals Healthcare Workers’ Perspectives on the Upcoming COVID-19 Vaccine in Terms of Their Exposure to the Influenza Vaccine in Riyadh, Saudi Arabia: A Cross-Sectional Study

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 465
Author(s):  
Leena R. Baghdadi ◽  
Shatha G. Alghaihb ◽  
Alanoud A. Abuhaimed ◽  
Dania M. Alkelabi ◽  
Rawan S. Alqahtani
Keyword(s):  
Saudi Arabia ◽  
Influenza Vaccine ◽  
Work Experience ◽  
Healthcare Workers ◽  
Seasonal Influenza ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Seasonal Influenza Vaccine ◽  
History Of

In 2019, a novel severe acute respiratory syndrome (SARS-CoV-2 (COVID-19)) caused a global pandemic. There was an urgent need to develop a vaccine against COVID-19 to reduce its spread and economic burden. The main objective of this study was to understand the attitudes and concerns of healthcare workers (HCWs) towards the upcoming COVID-19 vaccine, whether their decision was influenced by their history of taking the seasonal influenza vaccine, and factors that influence the acceptance of the upcoming COVID-19 vaccine. This was a cross-sectional study conducted in Riyadh, Saudi Arabia. We selected and surveyed 356 HCWs via an electronic self-administered questionnaire. A total of 61.16% of HCWs were willing to receive the COVID-19 vaccine, and 55.9% of them had received the seasonal influenza vaccine in the preceding year (2019–2020). The strongest predictors for taking the COVID-19 vaccine were the HCWs’ belief that the COVID-19 vaccine would be safe, needed even for healthy people, that all HCWs should be vaccinated against COVID-19, and that HCWs will have time to take the vaccine. Being female, being middle aged, having <5 years of work experience, having no fear of injections, and being a non-smoker were predictive factors for taking the upcoming COVID-19 vaccine. No associations were found between the intention to take the COVID-19 vaccine and a history of taking the seasonal influenza vaccine.

scholarly journals Mapping the inequality of the global distribution of seasonal influenza vaccine

2021 ◽  
pp. 0308518X2199835
Author(s):  
Yen Ching Yau ◽  
Michael T Gastner
Keyword(s):  
Influenza Vaccine ◽  
Respiratory Diseases ◽  
Seasonal Influenza ◽  
Developed Countries ◽  
Essential Medicines ◽  
World Health ◽  
Equitable Access ◽  
Seasonal Influenza Vaccine ◽  
Choropleth Map ◽  
Vaccine Distribution

With an estimated annual worldwide death toll of between 290 000 and 650 000, seasonal influenza remains one of the deadliest respiratory diseases. Influenza vaccines provide moderate to high protection and have been on the World Health Organization’s Model List of Essential Medicines since 1979. Approximately 490 million doses of influenza vaccine are produced per year, but an investigation of geographic allocation reveals enormous disparities. Here, we present two maps that visualise the inequality of the distribution across 195 countries: a conventional choropleth map and a cartogram. In combination, these two maps highlight the widespread lack of coverage in Africa and many parts of Asia. As COVID-19 vaccines are now being distributed in developed countries, data for seasonal influenza vaccine distribution emphasises the need for policymakers to ensure equitable access to COVID-19 vaccines.

Sign in / Sign up

Export Citation Format

Share Document